Overview

• The Supreme Court ruled that the plaintiffs lacked standing to challenge the FDA's mifepristone approval.
• The ruling means mifepristone remains available, but the court did not address the drug's safety or FDA's decision.
• Legal experts warn that new challenges to mifepristone are likely, potentially using different plaintiffs or legal strategies.
• The decision has significant implications for medication abortion access and ongoing state-level abortion restrictions.
• Public opinion largely supports maintaining access to mifepristone, with many voters viewing the ruling favorably.